MedTrace Logo

Real-world Health Outcomes in Canadian Patients Using Semaglutide

NCT04175665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1133

Last updated 2020-02-21

No results posted yet for this study

Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are an injectable, non-insulin therapy for patients with type 2 diabetes (T2D). Semaglutide (Ozempic®) is the newest GLP-1 RA to become available in Canada in 2018, and is administered subcutaneously once-weekly. In clinical trials, semaglutide has been superior to placebo and other antihyperglycemic agents in HbA1c reduction and body weight loss. However, there is little real-world evidence available on the effectiveness of semaglutide in real-world clinical practice.

To better understand the effectiveness of semaglutide on clinical outcomes in a real-world setting, this retrospective cohort study will use the Canadian LMC Diabetes Registry to examine the effects of semaglutide on glycemic control, body weight, and other clinical outcomes in patients with T2D who initiate once-weekly semaglutide as part of usual clinical care in a diabetes specialist practice group in Canada.

Conditions

Interventions

DRUG

Semaglutide

Prescription for semaglutide as part of usual clinical practice

Sponsors & Collaborators

  • LMC Diabetes & Endocrinology Ltd.

    lead OTHER

Principal Investigators

  • Ronnie Aronson, MD · LMC Diabetes & Endocrinology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-06
Primary Completion
2020-02-09
Completion
2020-02-09

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175665 on ClinicalTrials.gov